eNOS Antibody - BSA Free

Immunohistochemistry-Paraffin: eNOS Antibody - BSA Free [NB300-500]

Immunohistochemistry-Paraffin: eNOS Antibody - BSA Free [NB300-500] - Mouse Carotid Artery stained with eNOS antibody. Image from verified customer review.

Immunohistochemistry: eNOS Antibody - BSA Free [NB300-500]

Immunohistochemistry: eNOS Antibody - BSA Free [NB300-500] - Staining of representative pulmonary artery endothelial cells from rats subjected to CON=Control Group, ALI=Acute lung injury Group, LV=Low tidal volume Group, VLV=Very low tidal volume Group, MV=Large tidal volume Group. Dark brown staining of indicates eNOS-positive cells. Magnification x400.

Immunohistochemistry: eNOS Antibody - BSA Free [NB300-500] -

Expression of endothelial markers indicate functional endothelium in TEVG.A. Whole mount staining of native aorta and TEVG. VE-cadherin is a marker of cellular borders of endothelial cells (green). Endothelial nitric oxide synthase (eNOS) is a marker of a functional endothelium (red). DAPI is a nuclear stain (blue). B. Real-time PCR analysis of ephrinB2 and eNOS. Ephrin-B2, a marker of arterial vessels. (n = 5–10 in each group)

Western Blot: eNOS Antibody - BSA Free [NB300-500] -

Western Blot: eNOS Antibody - BSA Free [NB300-500] - Mevalonate pathway inhibitors reversed fractionated-radiation–induced suppression of KLF2 & its downstream target molecules. Representative Western blot analysis & quantification of KLF2, TM, & eNOS 4 h after exposure to five fractions of 2 Gy (a) in presence or absence of atorvastatin (1 μM) or GT3 (5 μM) & (b) in presence or absence of GGTi (10 μM) (n = 3). beta-actin served as a loading control. (n, number of independent experiments performed; a, significant statistical difference between nonirradiated & irradiated groups; b, significant statistical difference between fractionated irradiation & single exposure; *, p < 0.05; **, p < 0.01; ***, p < 0.001). Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/32382091), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: eNOS Antibody - BSA Free [NB300-500] -

Western Blot: eNOS Antibody - BSA Free [NB300-500] - Upregulation of HMG-CoA reductase in shPLD2 cells decreases eNOS expression. (A) Representative western blot of HMG-CoA reductase in Scramble & shPLD2 cells. The regions of the Western blots containing the HMG-CoA reductase & actin immunoreactive bands were scanned & the relative abundance of the individual samples quantified using an Odyssey CLx imaging system (B) Quantification of western blots with HMG-CoA reductase normalized to actin (n = 4 experiments). (C) N-SIM microscopy of HMG-CoA reductase; Bar, 7.5 μM. (D) RT-PCR of HMG-CoA reductase in Scramble & shPLD2 cells (n = 3). (E) Western blot of eNOS after treatment with NFOT & Simvastatin. Representative image of 3 experiments. The regions of the Western blots (Suppl. Figure 2) containing the eNOS & actin immunoreactive bands were scanned & the relative abundance of the individual samples quantified using an Odyssey CLx imaging system. (F) Quantification of western blots with eNOS levels normalized to actin (n = 3). Comparisons without bars made to untreated Scramble values. (G) eNOS activity after treatment with Simvastatin (n = 7). Mean ± SEM; *p < 0.05; **p < 0.01; ***p ≤ 0.001; One-way ANOVA with Bonferroni’s Multiple Comparison Test. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/28831159), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: eNOS Antibody - BSA Free [NB300-500] -

Western Blot: eNOS Antibody - BSA Free [NB300-500] - The human PLD2 polymorphism R172C does not alter eNOS signaling but does decrease caveolin-1 protein levels. Overexpression of HA-tagged hPLD2 (A) & HA-R172C-PLD2 (B) in HeLa cells, visualized using anti-HA immunofluorescent staining (green). Arrowhead, PLD2 localization in filopodia; chevron, in peripheral actin ruffles; *, in dorsal actin ruffles; arrow, in subcortical actin network. Bar, 7.5 μM. Representative image of multiple experiments. (C) Representative western blot of eNOS after transfection of HA-hPLD2 or HA-R172C-PLD2 into shPLD2 cells. The regions of the Western blots containing the eNOS & actin immunoreactive bands were scanned & the relative abundance of the individual samples quantified using an Odyssey CLx imaging system. (D) Quantification of western blotting with eNOS levels normalized to actin (n = 3). (E) eNOS activity as measured by nitrate formation (n = 7). Lane 1 vs 2, P = 0.0021; lane 2 vs 3, P = 0.00035; lane 2 vs 4, P = 0.00012. (F–I) N-SIM microscopy of plasma membrane eNOS & caveolin-1. Bar, 7.5 μM. Representative image of multiple Scramble or shPLD2 cells imaged. Cells in H & I were selected for imaging based on expression of HA-hPLD2 or HA-R172C-PLD2 as visualized by anti-HA immunofluorescence in a separate channel (not shown). Mean ± SEM; *p < 0.05; **p < 0.01; ***p ≤ 0.001; One-way ANOVA with Bonferroni’s Multiple Comparison Test. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/28831159), licensed under a CC-BY license. Not internally tested by Novus Biologicals.